NEW ORLEANS -- Participants with obesity achieved weight loss on par with bariatric surgery and had improvements in two obesity-related conditions while taking a once-weekly investigational triple hormone receptor agonist, the phase III TRIUMPH-1 study showed.
In 2,339 adults, mean change in body weight by week 80 was -19% with retatrutide 4 mg, -25.9% with 9 mg, and -28.3% with 12 mg, compared with -2.2% with placebo when paired with lifestyle counseling (P<0.001 for all groups vs placebo).
This translated to an average weight loss of up to 70.3 lbs (31.9 kg) with the highest dose, Ania Jastreboff, MD, PhD, of Yale University School of Medicine in New Haven, Connecticut said at the American Diabetes Association (ADA) Scientific Sessions. Weight loss was 30.3% with 12 mg, or 85 lbs (38.5 kg) at the end of a 24-week extension phase that involved a subset of participants.
"These are bariatric-surgery levels of weight reduction," Jastreboff said during a press conference.
Impacts on osteoarthritis and obstructive sleep apnea (OSA) were also primary endpoints.
